Skip to main content
Erschienen in: Annals of Surgical Oncology 8/2013

01.08.2013 | Breast Oncology

Impact of Multifocality and Lymph Node Metastasis on the Prognosis and Management of Microinvasive Breast Cancer

verfasst von: Nimmi S. Kapoor, MD, Jaime Shamonki, MD, Myung-Shin Sim, PhD, Cathie T. Chung, MD, Armando E. Giuliano, MD

Erschienen in: Annals of Surgical Oncology | Ausgabe 8/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

There are few data on the long-term outcome of patients with microinvasive (T1mi) breast cancer. Moreover, predictors of lymph node involvement and the impact of multifocal microinvasion are not well understood.

Methods

Patients with T1mi cancer, defined as tumors ≤1 mm, surgically managed at our institute and who underwent axillary lymph node evaluation were identified. Specimen slides were independently reviewed. Multivariate analysis was used to identify factors predictive of lymph node involvement.

Results

Forty-five patients with T1mi cancer were identified. Median patient age was 52 years, and median size of in situ disease was 4 cm. Nine tumors (20.0 %) had more than one focus of microinvasion. Lymph nodes metastasis were identified in 9 patients: 1 macrometastasis (2.2 %), 4 micrometastases (8.9 %), and 4 isolated tumor cells (8.9 %). Seven of 9 patients with lymph node involvement underwent adjuvant chemotherapy. Estrogen receptor–negative invasive disease was a significant predictor of lymph node metastasis by multivariable analysis (p < 0.02). There was also a trend toward lymph node involvement in patients with multifocal microinvasion compared to unifocal disease (33.3 vs. 16.7 %, respectively). At a median follow-up of 83 months, 3 patients (6.3 %) had disease recurrence (1 local, 1 distant, 1 local and distant). All patients with recurrence initially had tumor-free lymph nodes and only one focus of microinvasion.

Conclusions

Microinvasive breast cancer clearly has the ability to metastasize and recur, but in this series, only 2 % of patients with nodal macrometastasis. Only two patients experienced local recurrence, neither of whom had lymph node metastasis. The importance of identifying nodal micrometastasis in T1mi disease needs to be further explored.
Literatur
1.
Zurück zum Zitat Hoda SA, Chiu A, Prasad ML, Giri D, Hoda RS. Are microinvasion and micrometastasis in breast cancer mountains or molehills? Am J Surg. 2000;180:305–8.PubMedCrossRef Hoda SA, Chiu A, Prasad ML, Giri D, Hoda RS. Are microinvasion and micrometastasis in breast cancer mountains or molehills? Am J Surg. 2000;180:305–8.PubMedCrossRef
2.
Zurück zum Zitat Fleming ID, Cooper JS, Henson DE, Hutter RV, Kennedy BJ, Murphy GP et al., editors. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven; 1997. Fleming ID, Cooper JS, Henson DE, Hutter RV, Kennedy BJ, Murphy GP et al., editors. AJCC cancer staging manual. 5th ed. Philadelphia: Lippincott-Raven; 1997.
3.
Zurück zum Zitat Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–7.PubMedCrossRef Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989;63:181–7.PubMedCrossRef
4.
Zurück zum Zitat Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg. 2000;191:1–6.PubMedCrossRef Rivadeneira DE, Simmons RM, Christos PJ, Hanna K, Daly JM, Osborne MP. Predictive factors associated with axillary lymph node metastases in T1a and T1b breast carcinomas: analysis in more than 900 patients. J Am Coll Surg. 2000;191:1–6.PubMedCrossRef
5.
Zurück zum Zitat Coombs NJ, Boyages J. Multifocal and multicentric breast cancer: does each focus matter? J Clin Oncol. 2005;23:7497–502.PubMedCrossRef Coombs NJ, Boyages J. Multifocal and multicentric breast cancer: does each focus matter? J Clin Oncol. 2005;23:7497–502.PubMedCrossRef
6.
Zurück zum Zitat Andea AA, Bouwman D, Walis T, Visscher DW. Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma. Cancer. 2004;100:20–7.PubMedCrossRef Andea AA, Bouwman D, Walis T, Visscher DW. Correlation of tumor volume and surface area with lymph node status in patients with multifocal/multicentric breast carcinoma. Cancer. 2004;100:20–7.PubMedCrossRef
7.
Zurück zum Zitat Chung A, Huynh K, Kidner T, Mirzadehgan P, Sim MS, Giuliano AE et al. Comparison of outcomes of breast conserving therapy in multifocal or multicentric and unifocal invasive breast cancer. J Am Coll Surg. 2012;215:137–46.PubMedCrossRef Chung A, Huynh K, Kidner T, Mirzadehgan P, Sim MS, Giuliano AE et al. Comparison of outcomes of breast conserving therapy in multifocal or multicentric and unifocal invasive breast cancer. J Am Coll Surg. 2012;215:137–46.PubMedCrossRef
8.
Zurück zum Zitat Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, et al. editors. AJCC cancer staging manual. 7th ed. Springer; 2010. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, et al. editors. AJCC cancer staging manual. 7th ed. Springer; 2010.
9.
Zurück zum Zitat Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg. 1990;125: 1298–301.PubMedCrossRef Wong JH, Kopald KH, Morton DL. The impact of microinvasion on axillary node metastases and survival in patients with intraductal breast cancer. Arch Surg. 1990;125: 1298–301.PubMedCrossRef
10.
Zurück zum Zitat Ko BS, Lim WS, Kim HJ, Yu JH, Lee JW, Kwan SB, et al. Risk factor for axillary lymph node metastases in microinvasive breast cancer. Ann Surg Oncol. 2012;19:212–6.PubMedCrossRef Ko BS, Lim WS, Kim HJ, Yu JH, Lee JW, Kwan SB, et al. Risk factor for axillary lymph node metastases in microinvasive breast cancer. Ann Surg Oncol. 2012;19:212–6.PubMedCrossRef
11.
Zurück zum Zitat Lyons JM, Stempel M, Van Zee KJ, Cody HS. Axillary node staging for microinvasive breast cancer: is it justified? Ann Surg Oncol. 2012;19:3416–21. Lyons JM, Stempel M, Van Zee KJ, Cody HS. Axillary node staging for microinvasive breast cancer: is it justified? Ann Surg Oncol. 2012;19:3416–21.
12.
Zurück zum Zitat Guth AA, Mercado C, Roses DF, Darvishian F, Singh B, Cangiarella JF et al. Microinvasive breast cancer and the role of sentinel node biopsy: an institutional experience and review of the literature. Breast J. 2008;14:335–9.PubMedCrossRef Guth AA, Mercado C, Roses DF, Darvishian F, Singh B, Cangiarella JF et al. Microinvasive breast cancer and the role of sentinel node biopsy: an institutional experience and review of the literature. Breast J. 2008;14:335–9.PubMedCrossRef
13.
Zurück zum Zitat Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657–63.PubMedCrossRef Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW et al. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25:3657–63.PubMedCrossRef
14.
Zurück zum Zitat Katz A, Gage I, Evans S, Shaffer M, Fleury T, Smith FP, et al. Sentinel lymph node positivity of patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg. 2006;191:761–6.PubMedCrossRef Katz A, Gage I, Evans S, Shaffer M, Fleury T, Smith FP, et al. Sentinel lymph node positivity of patients with ductal carcinoma in situ or microinvasive breast cancer. Am J Surg. 2006;191:761–6.PubMedCrossRef
15.
Zurück zum Zitat Intra M, Zurrida S, Maffini F, Sonzogni A, Trifirò G, Gennari R, et al. Sentinel lymph node metastasis in microinvasive breast cancer. Ann Surg Oncol. 2003;10:1160–5.PubMedCrossRef Intra M, Zurrida S, Maffini F, Sonzogni A, Trifirò G, Gennari R, et al. Sentinel lymph node metastasis in microinvasive breast cancer. Ann Surg Oncol. 2003;10:1160–5.PubMedCrossRef
16.
Zurück zum Zitat Zavotsky J, Hansen N, Brennan MB, Turner RR, Giuliano AE. Lymph node metastasis from ductal carcinoma in situ with microinvasion. Cancer. 1999;85:2439–43.PubMedCrossRef Zavotsky J, Hansen N, Brennan MB, Turner RR, Giuliano AE. Lymph node metastasis from ductal carcinoma in situ with microinvasion. Cancer. 1999;85:2439–43.PubMedCrossRef
17.
Zurück zum Zitat Klauber-DeMore N, Tan LK, Liberman L, Kaptain S, Fey J, Borgen P et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in situ and ductal carcinoma-in situ with microinvasion? Ann Surg Oncol. 2000;7:636–42.PubMedCrossRef Klauber-DeMore N, Tan LK, Liberman L, Kaptain S, Fey J, Borgen P et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ductal carcinoma-in situ and ductal carcinoma-in situ with microinvasion? Ann Surg Oncol. 2000;7:636–42.PubMedCrossRef
18.
Zurück zum Zitat Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED et al. Prognostic classification of breast ductal carcinoma in situ. Lancet. 1995;345:1154–7.PubMedCrossRef Silverstein MJ, Poller DN, Waisman JR, Colburn WJ, Barth A, Gierson ED et al. Prognostic classification of breast ductal carcinoma in situ. Lancet. 1995;345:1154–7.PubMedCrossRef
19.
Zurück zum Zitat Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011;306:385–93.PubMedCrossRef Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011;306:385–93.PubMedCrossRef
20.
Zurück zum Zitat Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, et al. Effect of occultmetastases on survival in node-negative breast cancer. N Engl J Med. 2011;364:412–21.PubMedCrossRef Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, et al. Effect of occultmetastases on survival in node-negative breast cancer. N Engl J Med. 2011;364:412–21.PubMedCrossRef
21.
Zurück zum Zitat Kapoor NS, Sim MS, Lin J, Giuliano AE. Long-term outcome of patients managed with sentinel lymph node biopsy alone for node-negative invasive breast cancer. Arch Surg. 2012;147:1047–52.PubMed Kapoor NS, Sim MS, Lin J, Giuliano AE. Long-term outcome of patients managed with sentinel lymph node biopsy alone for node-negative invasive breast cancer. Arch Surg. 2012;147:1047–52.PubMed
22.
Zurück zum Zitat Hansen NM, Grube B, Ye X, Turner RR, Brenner RJ, Sim MS, et al. Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol. 2009;27:4679–84.PubMedCrossRef Hansen NM, Grube B, Ye X, Turner RR, Brenner RJ, Sim MS, et al. Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol. 2009;27:4679–84.PubMedCrossRef
23.
Zurück zum Zitat Tvedskov TF, Jensen MB, Balslev E, Ejlertsen B, Kroman N. Stage migration after introduction of sentinel lymph node dissection in breast cancer treatment in Denmark: a nationwide study. Eur J Cancer. 2011;47:872–8.PubMedCrossRef Tvedskov TF, Jensen MB, Balslev E, Ejlertsen B, Kroman N. Stage migration after introduction of sentinel lymph node dissection in breast cancer treatment in Denmark: a nationwide study. Eur J Cancer. 2011;47:872–8.PubMedCrossRef
24.
Zurück zum Zitat Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134:459–78.PubMedCrossRef Murphy CC, Bartholomew LK, Carpentier MY, Bluethmann SM, Vernon SW. Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review. Breast Cancer Res Treat. 2012;134:459–78.PubMedCrossRef
25.
Zurück zum Zitat Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology. 2006;71:1–9.PubMed Chlebowski RT, Geller ML. Adherence to endocrine therapy for breast cancer. Oncology. 2006;71:1–9.PubMed
26.
Zurück zum Zitat Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.PubMedCrossRef Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305:569–75.PubMedCrossRef
27.
Zurück zum Zitat Morrow M, Harris JR. Ductal carcinoma in situ and microinvasive carcinoma. In: Diseases of the breast. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2010. p. 349–62. Morrow M, Harris JR. Ductal carcinoma in situ and microinvasive carcinoma. In: Diseases of the breast. 4th ed. Philadelphia: Lippincott Williams & Wilkins, 2010. p. 349–62.
28.
Zurück zum Zitat Rosner D, Lane WW, Pentrante R. Ductal carcinoma in situ with microinvasion. A curable entity using surgery alone without need for adjuvant therapy. Cancer. 1991;67:1498–503.PubMedCrossRef Rosner D, Lane WW, Pentrante R. Ductal carcinoma in situ with microinvasion. A curable entity using surgery alone without need for adjuvant therapy. Cancer. 1991;67:1498–503.PubMedCrossRef
29.
Zurück zum Zitat Kinne DW, Petrek JA, Osborne MP, Fracchia AA, DePalo AA, Rosen PP, et al. Breast carcinoma in situ. Arch Surg. 1989;124:33–6.PubMedCrossRef Kinne DW, Petrek JA, Osborne MP, Fracchia AA, DePalo AA, Rosen PP, et al. Breast carcinoma in situ. Arch Surg. 1989;124:33–6.PubMedCrossRef
Metadaten
Titel
Impact of Multifocality and Lymph Node Metastasis on the Prognosis and Management of Microinvasive Breast Cancer
verfasst von
Nimmi S. Kapoor, MD
Jaime Shamonki, MD
Myung-Shin Sim, PhD
Cathie T. Chung, MD
Armando E. Giuliano, MD
Publikationsdatum
01.08.2013
Verlag
Springer US
Erschienen in
Annals of Surgical Oncology / Ausgabe 8/2013
Print ISSN: 1068-9265
Elektronische ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-2924-7

Weitere Artikel der Ausgabe 8/2013

Annals of Surgical Oncology 8/2013 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

CME: 2 Punkte

Prof. Dr. med. Gregor Antoniadis Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

CME: 2 Punkte

Dr. med. Benjamin Meyknecht, PD Dr. med. Oliver Pieske Das Webinar S2e-Leitlinie „Distale Radiusfraktur“ beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

CME: 2 Punkte

Dr. med. Mihailo Andric
Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.